ArticleFrontiers in medicine2022

Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review.

Jun Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.